237 related articles for article (PubMed ID: 31259822)
21. Langerhans cell histiocytosis and Erdheim-Chester disease overlap syndrome with bone marrow involvement and type 2 diabetes mellitus.
Chen M; Ding C; Lu T; Niu N; Han B
Ann Hematol; 2018 Jan; 97(1):189-192. PubMed ID: 28889238
[No Abstract] [Full Text] [Related]
22. Langerhans cell histiocytosis and Erdheim-Chester disease, both with cutaneous presentations, and papillary thyroid carcinoma all harboring the BRAF(V600E) mutation.
Johnson WT; Patel P; Hernandez A; Grandinetti LM; Huen AC; Marks S; Ho J; Monaco SE; Jaffe R; Picarsic J
J Cutan Pathol; 2016 Mar; 43(3):270-5. PubMed ID: 26454140
[TBL] [Abstract][Full Text] [Related]
23. Association of both Langerhans cell histiocytosis and Erdheim-Chester disease linked to the BRAFV600E mutation.
Hervier B; Haroche J; Arnaud L; Charlotte F; Donadieu J; Néel A; Lifermann F; Villabona C; Graffin B; Hermine O; Rigolet A; Roubille C; Hachulla E; Carmoi T; Bézier M; Meignin V; Conrad M; Marie L; Kostrzewa E; Michot JM; Barete S; Taly V; Cury K; Emile JF; Amoura Z;
Blood; 2014 Aug; 124(7):1119-26. PubMed ID: 24894769
[TBL] [Abstract][Full Text] [Related]
24. [Erdheim-Chester disease-A histiocytic multisystem disease with unusual renal involvement].
Dasdelen S; Büschek F
Internist (Berl); 2020 Sep; 61(9):969-979. PubMed ID: 32785740
[TBL] [Abstract][Full Text] [Related]
25. Dabrafenib and steroids for the treatment of Erdheim-Chester disease with extensive CNS involvement: a case report.
Yuen CA; Bao S; Aung MS; Shishodia R; Kong XT
Per Med; 2024; 21(2):71-78. PubMed ID: 38275171
[TBL] [Abstract][Full Text] [Related]
26. Erdheim-Chester Disease: A Case Report of BRAF V600E-Negative, MAP2K1-Positive ECD Diagnosed by Blood Next-Generation Sequencing Assay and a Brief Literature Review.
Aggarwal A; Taychert M; Hasanin L; Doll D; Basuino MG; Hasanein H
Oncology (Williston Park); 2023 Jul; 37(7):298-302. PubMed ID: 37499251
[TBL] [Abstract][Full Text] [Related]
27. Association between Ischemic Stroke and Erdheim-Chester Disease: A Case Report and Review of Literature.
Fargeot G; Stefanizzi S; Depuydt S; Klapczynski F; Ameri A
J Stroke Cerebrovasc Dis; 2017 Aug; 26(8):e153-e155. PubMed ID: 28623120
[TBL] [Abstract][Full Text] [Related]
28. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation.
Haroche J; Cohen-Aubart F; Emile JF; Arnaud L; Maksud P; Charlotte F; Cluzel P; Drier A; Hervier B; Benameur N; Besnard S; Donadieu J; Amoura Z
Blood; 2013 Feb; 121(9):1495-500. PubMed ID: 23258922
[TBL] [Abstract][Full Text] [Related]
29. Advances in Understanding and Management of Erdheim-Chester Disease.
Kulkarni AM; Gayam PKR; Aranjani JM
Life Sci; 2024 Jul; 348():122692. PubMed ID: 38710283
[TBL] [Abstract][Full Text] [Related]
30. Multisystem Erdheim-Chester disease presenting with pericardial effusion confirmed by the effusion cytology specimen.
Dai S; Su X; Liu WP; Wu Y
Cardiovasc Pathol; 2024; 70():107625. PubMed ID: 38417471
[TBL] [Abstract][Full Text] [Related]
31. Erdheim-Chester disease with bilateral orbital masses and multi-systemic symptoms: two case reports.
Qiao J; Ma R; Peng X; He W
World J Surg Oncol; 2023 Jul; 21(1):233. PubMed ID: 37525276
[TBL] [Abstract][Full Text] [Related]
32. The clinical spectrum and prognostic factors of Erdheim-Chester disease and mixed Langerhans cell histiocytosis and Erdheim-Chester disease.
Dai JW; Lin H; Chang L; Li J; Zhou DB; Cao XX
Ann Hematol; 2023 Dec; 102(12):3335-3343. PubMed ID: 37922006
[TBL] [Abstract][Full Text] [Related]
33. Clinical and Neuroimaging Manifestations of Erdheim-Chester Disease: A Review.
Garg N; Lavi ES
J Neuroimaging; 2021 Jan; 31(1):35-44. PubMed ID: 32920940
[TBL] [Abstract][Full Text] [Related]
34. Erdheim-Chester Disease With Cardiovascular Involvement and BRAF V600E Mutation.
Okamura K; Suematsu Y; Morizumi S; Kawata M; Dai Y; Yamakawa M; Ono M
Circ J; 2016 Jun; 80(7):1657-9. PubMed ID: 27296272
[No Abstract] [Full Text] [Related]
35. Erdheim-Chester Disease: a comprehensive review of the literature.
Mazor RD; Manevich-Mazor M; Shoenfeld Y
Orphanet J Rare Dis; 2013 Sep; 8():137. PubMed ID: 24011030
[TBL] [Abstract][Full Text] [Related]
36. Dramatic Efficacy of Interferon and Vemurafenib on Psychiatric Symptoms Revealing
Razanamahery J; Abdallahoui M; Chabridon G; Fromont A; Tarris G; Idbaih A; Comby PO; Godard F; Haroche J; Audia S; Bonnotte B
Front Immunol; 2022; 13():918613. PubMed ID: 35874752
[TBL] [Abstract][Full Text] [Related]
37. Case report of a patient with Erdheim-Chester disease presenting with neuro-endocrine symptoms and negative for BRAF mutation.
Lu L; Zhou J; Yan X; Jin R; Deng S; Lu W; Chen D
Medicine (Baltimore); 2023 May; 102(20):e33846. PubMed ID: 37335698
[TBL] [Abstract][Full Text] [Related]
38. Erdheim-Chester Disease Successfully Treated with Front-Line Single-Agent Dabrafenib.
Salama H; Fahed Alzayed M; Alharbi KG; Khattak Z; Omer MH; Tahir L; ALhejazi A
Am J Case Rep; 2022 Feb; 23():e935090. PubMed ID: 35171900
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of intermediate-dose cytarabine in central nervous system-relapsed wild-type BRAF Erdheim-Chester disease.
Cao XX; Niu N; Sun J; Zhou DB; Li J
Ann Hematol; 2018 Jan; 97(1):185-187. PubMed ID: 28831599
[No Abstract] [Full Text] [Related]
40. [Erdheim-Chester disease].
Mazor RD; Shoenfeld Y
Harefuah; 2014 Jul; 153(7):389-91, 434, 433. PubMed ID: 25189027
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
